6 days ago

Jefferies Backs Five Indian CRDMO Stocks With Upside

Jefferies is a financial research firm that studied Indian companies making medicines and drug ingredients for other companies.

It believes five of these companies could perform well.

The five companies are Anthem Biosciences, Gland Pharma, Divi’s Laboratories, Piramal Pharma and Sai Life Sciences.

Anthem Biosciences has the biggest possible share-price gain in Jefferies’ estimates, at 20%.

Sai Life Sciences and Divi’s Laboratories are Jefferies’ favorite companies in the group.

The sector grew strongly during the June quarter, with sales rising faster than in recent quarters.

Many companies also reported strong orders and requests from large pharmaceutical companies.

These ratings are Jefferies’ opinions, not guarantees that investors will make money.

Key facts

Jefferies sector growth: Companies covered by Jefferies recorded 19% year-on-year growth in the June quarter, the highest rate in seven quarters.
Highest potential upside: Anthem Biosciences: 20%, based on Jefferies’ target price of Rs 1,050.
Top picks: Sai Life Sciences and Divi’s Laboratories remained Jefferies’ top picks.
Gland Pharma target: Rs 3,350, implying 19.6% potential upside; its rating was upgraded from ‘Hold’ to ‘Buy’.
Divi’s Laboratories target: Rs 10,200, implying 17.5% potential upside.
Sai Life Sciences target: Rs 1,610, implying 10.7% potential upside.
Order visibility: Sai Life Sciences had more than 90% of targeted FY27 revenue covered by orders, while Anthem Biosciences had more than 80% of targeted FY27 CRDMO sales covered.

financialexpress.com · 6 days ago